What is William Blair’s Forecast for MRSN FY2024 Earnings?

Mersana Therapeutics, Inc. (NASDAQ:MRSN) – Investment analysts at William Blair issued their FY2024 earnings estimates for Mersana Therapeutics in a research note issued on Wednesday, February 5th. William Blair analyst A. Hsieh anticipates that the company will post earnings per share of ($0.68) for the year. William Blair has a “Outperform” rating on the stock. The consensus estimate for Mersana Therapeutics’ current full-year earnings is ($0.61) per share. William Blair also issued estimates for Mersana Therapeutics’ FY2025 earnings at ($0.91) EPS, FY2026 earnings at ($0.89) EPS, FY2027 earnings at ($0.93) EPS, FY2028 earnings at ($1.15) EPS and FY2029 earnings at ($1.29) EPS.

Mersana Therapeutics (NASDAQ:MRSN) last announced its quarterly earnings data on Wednesday, November 13th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.08. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. The company had revenue of $12.60 million during the quarter, compared to analysts’ expectations of $7.53 million. During the same quarter last year, the company earned ($0.35) EPS. Mersana Therapeutics’s revenue for the quarter was up 63.6% compared to the same quarter last year.

A number of other brokerages have also recently issued reports on MRSN. Citigroup initiated coverage on shares of Mersana Therapeutics in a report on Friday, November 15th. They issued a “buy” rating and a $5.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and set a $4.00 price target (down previously from $7.00) on shares of Mersana Therapeutics in a report on Friday, January 10th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $5.57.

Mersana Therapeutics Trading Down 6.7 %

Shares of Mersana Therapeutics stock opened at $0.70 on Monday. Mersana Therapeutics has a 12-month low of $0.49 and a 12-month high of $6.28. The company has a quick ratio of 2.35, a current ratio of 2.35 and a debt-to-equity ratio of 13.35. The business’s 50 day moving average is $1.29 and its 200-day moving average is $1.67. The stock has a market cap of $86.47 million, a P/E ratio of -1.15 and a beta of 1.39.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in MRSN. China Universal Asset Management Co. Ltd. bought a new stake in shares of Mersana Therapeutics in the fourth quarter valued at approximately $37,000. SG Americas Securities LLC lifted its position in shares of Mersana Therapeutics by 28.7% during the 4th quarter. SG Americas Securities LLC now owns 112,291 shares of the company’s stock valued at $161,000 after acquiring an additional 25,058 shares during the period. Avanza Fonder AB acquired a new stake in shares of Mersana Therapeutics during the 4th quarter worth $81,000. JPMorgan Chase & Co. lifted its position in Mersana Therapeutics by 18.9% during the third quarter. JPMorgan Chase & Co. now owns 2,351,359 shares of the company’s stock worth $4,444,000 after purchasing an additional 374,460 shares during the period. Finally, Exome Asset Management LLC acquired a new stake in Mersana Therapeutics during the third quarter worth about $2,227,000. Institutional investors and hedge funds own 93.92% of the company’s stock.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.